Search

Displaying results 4511 - 4520 of 10000 in total
  1. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic

    Categories: Enzymes and Coenzymes, Blood and Blood Forming Organs
  2. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

  3. Drug

    Methionine

    go.drugbank.com/drugs/DB00134
    ApprovedInvestigationalNutraceutical

    A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.

    Mixtures: Aminosyn II and Dextrose, Aminosyn II and DextroseCategories: Amino Acids, Peptides, and Proteins
  4. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    Specifically, the amino acid sequence of MAXY-G34 differs from that of human wild type G-CSF at residues 16, 34, 40, 105 and 159. … This was accomplished by removing the three lysine residues at positions 16, 34 and 40, and replacing them with arginine, and substituting two new lysine residues at positions 105 and 159.

    Categories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and Proteins
  5. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately … Therapeutically, 2-deoxyglucose is an investigational drug that is being studied as an anticancer and antiviral agent.

  6. Drug

    Poa pratensis pollen

    go.drugbank.com/drugs/DB10366
    Approved

    Poa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.

    Mixtures: K-O-R-T and Sweet Vernal Standardized Grass Pollen Mix, K-O-R-T and Sweet Vernal Standardized Grass Pollen Mix
  7. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

    Categories: Hypnotics and Sedatives
  8. Drug

    Lazuvapagon

    go.drugbank.com/drugs/DB19046
    Investigational

    Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).

  9. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Categories: Blood and Blood Forming Organs
  10. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing